Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Import to Russia (July 2019)

Friday, September 20, 2019

In July 2019, Russia imported 61.5 bln RUB worth of ready-made pharmaceuticals (free circulation prices, VAT included), which is in monetary terms (rubles) +31.5% higher than that of July 2018 and the highest volume since August 2010. Higher dynamics were witnessed in June 2016. However, the dynamics in physical terms are only +7.3%, with the import volume of 183.3 bln units.

Between January and July 2019, Russia imported 336.3 bln RUB worth of ready-made pharmaceuticals (free circulation prices, VAT included), which is in monetary terms (rubles) 14.5% higher than that of the same period in 2018. As for in-bulk pharmaceuticals, Russia imported 65,6 bln RUB, with the dynamics of +4.5%. In physical terms, Russia imported 1.03 bln units of ready-made drugs, with the dynamics of -2.1% in physical terms (units), or 1.86 bln minimum dosage units (MDU), with the dynamics of -28.4%.

Among the top 20 companies with the highest import volume in monetary terms for the period, BMS has the highest dynamics, with a 3.5 times import. The company’s import amounts to over 5 bln RUB, with Opdivo accounting for over 70% of the import. The import of Opdivo has risen by 3.8 times in monetary terms, which is still not record-worthy, since the import of BMS’ Yervoy has risen by 8.3 times. BMS us followed by Astellas, with a 2 times increase. The import of a number of drugs has risen, in particular of Eligard (3.7 times increase) and Xtandi (2.1 times increase). Astellas also halted in-bulk imports of Flemoxin Solutab, Advagraf, Wilprafen and others, which was substituted by ready-made drug import.

As for in-bulk importers, the leaders are very few. Among the top 20 companies, Novartis has the highest dynamics, with a 4.7 times increase. The company has been in-bulk importing 7 trademarks since January, with Tafinlar and Jaakafi accounting for the highest percent of the import. Astellas is followed by Eisai, with a 2.4 times increase. Eisai has been importing only two trademarks, antitumor Halaven and Lenvima. Both drugs are packaged at the facilities of Pharmastandard in Ufa.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2018 – July 2019)

Share: